2020 Sarcoma

Scheme description
Testing of FFPE samples for sarcoma rearrangements/amplifications.
Disorders/Gene target(s)
Sarcoma, Ewings sarcoma, synovial sarcoma, well differentiated liposarcoma/de-differentiated liposarcomas, myxoid liposarcoma, alveolar rhabdomyosarcoma, FOXO1, endometrial stromal tumours, nodular fascitis, aneurysmal bone cysts, low-grade fibromyxoid sarcomas, sclerosing epitheliod sarcomas, extra-skeletal chondrosarcomas, clear cell sarcomas, desmoplastic small round cell tumour, alveolar soft part sarcoma ,EWSR1, DDIT3, SS18, MDM2, JAZ1, USP6, FUS, NR4A3, TFE3
Clinical cases
Three
Testing/analysis
Any
Sample type
Formalin fixed paraffin embedded sections supplied as
1) rolled sections,
2) slide mounted sections
or 3) rolled sections plus one slide mounted section for H&E staining.
Please indicate your sample choice when enrolling.
Techniques
FISH, Next generation sequencing, RT-PCR, RNA based methods
Assessment
Submit a clinical report to include:
• Genotyping of results
• Interpretation of the result
• Clerical accuracy
Performance criteria are applied.
Eligibility
All laboratories worldwide
Languages
English ONLY
ISO17043 Accredited EQA
Yes
EQA timeline
Sample dispatchSeptember 2020
Testing period6 weeks
Assessment resultsJanuary 2021
Final Summary reportFebruary 2021
Other information
Two "common" sarcomas will be sent out with either EWSR1 or SS18 rearrangements or MDM2 amplification along with one rarer sarcoma.
Fee
£260.00
GenQA code
2020SARC
« Return to EQA scheme list
Go to top